Merck in-licenses Evaxion vaccine candidate in a deal worth up to $600M
Source: SeekingAlpha
2025-09-25 08:04:48 ET
More on Evaxion Biotech ADS, Merck
- Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield
- Merck: Buy This Dividend Powerhouse While It's Cheap
- Merck & Co., Inc. (MRK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- Trump administration formally links Tylenol use in pregnancy to autism
- Trump considering website for consumers to buy discounted prescription drugs - report
Read the full article on Seeking Alpha
For further details see:
Merck in-licenses Evaxion vaccine candidate in a deal worth up to $600M
Evaxion Biotech A/S
NASDAQ: EVAX
EVAX Trading
-2.2% G/L:
$4.225 Last:
60,264 Volume:
$4.25 Open:
EVAX Latest News
March 02, 2026 08:00:00 am
Evaxion to announce business update and full year 2025 financial results on March 5, 2026
EVAX Stock Data
$28,519,826
7,782,965
N/A
6
N/A
Biotechnology & Life Sciences
Healthcare
DK
Hoersholm
